Silverman Joshua 4
4 · PharmaCyte Biotech, Inc. · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Silverman Joshua
DirectorCEO and President
Transactions
- Award
Common Stock
2025-12-12+575,000→ 575,000 total - Tax Payment
Common Stock
2025-12-12$1.02/sh−258,750$263,925→ 316,250 total
Holdings
- 50,000(indirect: By LLC)
Common Stock
Footnotes (1)
- [F1]Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.